Treatment Response in Kawasaki Disease Is Associated with Sialylation Levels of Endogenous but Not Therapeutic Intravenous Immunoglobulin G-Reference-Cited by-同舟云学术

Treatment Response in Kawasaki Disease Is Associated with Sialylation Levels of Endogenous but Not Therapeutic Intravenous Immunoglobulin G

Published:2013-12-06 Issue:12 Volume:8 Page:e81448
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ogata Shohei,Shimizu Chisato,Franco Alessandra,Touma Ranim,Kanegaye John T.,Choudhury Biswa P.,Naidu Natasha N.,Kanda Yutaka,Hoang Long T.,Hibberd Martin L.,Tremoulet Adriana H.,Varki Ajit,Burns Jane C.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference74 articles.

1. Kawasaki syndrome;JC Burns;Lancet,2004

2. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients;H Kato;Circulation,1996

3. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome;JW Newburger;N Engl J Med,1991

4. Resistance to intravenous immunoglobulin in children with Kawasaki disease;AH Tremoulet;J Pediatr,2008

5. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action;VS Negi;J Clin Immunol,2007

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Charting a course for global progress in PIDs by 2030 — proceedings from the IPOPI global multi-stakeholders’ summit (September 2023);Frontiers in Immunology;2024-06-27

2. Kawasaki Disease;Pediatric Cardiology;2024

3. Can we suppress chronic systemic inflammation and postpone age-related diseases by targeting the IgG glycome?;Expert Opinion on Therapeutic Targets;2023-10-28

4. Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies;Biotechnology Advances;2023-10

5. Kawasaki Disease;Pediatric Cardiology;2023